Cantor Fitzgerald Starts Harrow Health (HROW) at Overweight

Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Harrow Health (NASDAQ: HROW) with a Overweight rating and a price target of $76.00.

The analyst comments "We are initiating coverage of HROW with an Overweight rating and 12-month $76 price target. In our view, Harrow is on a path to become the leading diversified U.S. ophthalmology company. The business strategy involves converting legacy compounding pharmacy business (still ~$80M/year revenue at ~65% gross margin) to a branded, higher margin ophthalmic product business, led by dry eye product Vevye (~$600Mpeak in our model), which in 1Q25 was already #1 in per-prescriber volume for dry eye prescription products (i.e., Harrow just needs to increase prescriber base, which Vevye Access-for-All program is rapidly accomplishing)."

For an analyst ratings summary and ratings history on Harrow Health click here. For more ratings news on Harrow Health click here.

Shares of Harrow Health closed at $31.37 yesterday.

You May Also Be Interested In

• Freedom Broker Downgrades Workday (WDAY) to Hold
• Blue Owl leads $2.4B equipment financing for IREN's Canada data center
• Defense Secretary May Again Invite Hundreds of Senior Military Personnel to U.S. for Speech - WSJ